JP2017530176A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530176A5
JP2017530176A5 JP2017518804A JP2017518804A JP2017530176A5 JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5 JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017518804 A JP2017518804 A JP 2017518804A JP 2017530176 A5 JP2017530176 A5 JP 2017530176A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
group
independently selected
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530176A (ja
JP6820254B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/091614 external-priority patent/WO2016055028A1/en
Publication of JP2017530176A publication Critical patent/JP2017530176A/ja
Publication of JP2017530176A5 publication Critical patent/JP2017530176A5/ja
Application granted granted Critical
Publication of JP6820254B2 publication Critical patent/JP6820254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518804A 2014-10-10 2015-10-10 治療用化合物およびその使用 Expired - Fee Related JP6820254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014088315 2014-10-10
CNPCT/CN2014/088315 2014-10-10
PCT/CN2015/091614 WO2016055028A1 (en) 2014-10-10 2015-10-10 Therapeutic compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2017530176A JP2017530176A (ja) 2017-10-12
JP2017530176A5 true JP2017530176A5 (enExample) 2018-11-22
JP6820254B2 JP6820254B2 (ja) 2021-01-27

Family

ID=55652608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518804A Expired - Fee Related JP6820254B2 (ja) 2014-10-10 2015-10-10 治療用化合物およびその使用

Country Status (5)

Country Link
US (1) US10206931B2 (enExample)
EP (1) EP3204360B1 (enExample)
JP (1) JP6820254B2 (enExample)
CN (1) CN107108512B (enExample)
WO (1) WO2016055028A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック, インコーポレイテッド ブロモドメインインヒビターおよびその使用
AU2017213628B2 (en) 2016-02-05 2021-07-29 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
CN109715790A (zh) 2016-07-25 2019-05-03 埃皮兹姆公司 Crebbp相关的癌症疗法
WO2018107060A1 (en) 2016-12-09 2018-06-14 Denali Therapeutics Inc. Compounds, compositions and methods
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107325092B (zh) * 2017-08-07 2021-01-08 山东鲁宁药业有限公司 一种阿奇沙坦的制备新工艺
CN107643405B (zh) * 2017-09-19 2020-07-17 上海市肺科医院 一种基于自身抗体检测的肺癌诊断试剂盒及其应用
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
US20220135538A1 (en) * 2019-02-27 2022-05-05 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitors and methods for their use
EP3930759A4 (en) * 2019-02-27 2023-03-22 Cullgen (Shanghai), Inc. CYCLIC AMP-RESPONSIVE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE
US20230086702A1 (en) 2019-04-18 2023-03-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereof
WO2020257278A2 (en) * 2019-06-18 2020-12-24 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
TW202120095A (zh) * 2019-08-05 2021-06-01 美商美國禮來大藥廠 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
AU2021259814B2 (en) * 2020-04-25 2023-09-28 Pharmablock Sciences (Nanjing), Inc. CBP/EP300 inhibitor and use thereof
IL297437A (en) 2020-05-13 2022-12-01 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN116057045A (zh) 2020-06-05 2023-05-02 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
US20230250088A1 (en) * 2020-07-15 2023-08-10 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20240270695A1 (en) * 2021-01-12 2024-08-15 Chengdu Anticancer Bioscience Ltd Compounds, compositions and methods of treating disorders
WO2022226172A1 (en) * 2021-04-21 2022-10-27 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
WO2022231262A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
EP4433456A1 (en) * 2021-11-19 2024-09-25 Chengdu Anticancer Bioscience, Ltd. 1h-benzo[b]azepin-2(3h)-one compounds, compositions and methods of treating cancer
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3203952A (en) * 1962-12-04 1965-08-31 Upjohn Co Chloromethylsulfonamides of cyclic diamines
US3361750A (en) * 1963-03-21 1968-01-02 Squibb & Sons Inc Benzothiazepines
DE3800386A1 (de) * 1988-01-09 1989-07-20 Bayer Ag Verfahren zur herstellung von benzothiazepinon-derivaten
WO2006051851A1 (ja) * 2004-11-10 2006-05-18 Wakamoto Pharmaceutical Co., Ltd. 2,3,4,5-テトラヒドロ-1h-1,5-ベンゾジアゼピン誘導体、及び、医薬組成物
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
WO2012151512A2 (en) * 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類

Similar Documents

Publication Publication Date Title
JP2017530176A5 (enExample)
JP2019516757A5 (enExample)
JP2019516759A5 (enExample)
JP2017533250A5 (enExample)
JP2017537100A5 (enExample)
JP2017526696A5 (enExample)
JP2018501287A5 (enExample)
JP2017533249A5 (enExample)
JP2018510851A5 (enExample)
JP2017530984A5 (enExample)
JP2017533248A5 (enExample)
JP2017525740A5 (enExample)
JP2018507191A5 (enExample)
JP2018505169A5 (enExample)
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2016529312A5 (enExample)
JP2016510748A5 (enExample)
JP2017121233A5 (enExample)
JP2016513137A5 (enExample)
JP2014506601A5 (enExample)
JP2010522194A5 (enExample)
RU2015142102A (ru) Соединение для лечения рака
JP2019522055A5 (enExample)
JP2017502092A5 (enExample)
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.